CN1275915A - 具有免疫刺激和转移抑制功能的植物性发酵物质 - Google Patents
具有免疫刺激和转移抑制功能的植物性发酵物质 Download PDFInfo
- Publication number
- CN1275915A CN1275915A CN98810125A CN98810125A CN1275915A CN 1275915 A CN1275915 A CN 1275915A CN 98810125 A CN98810125 A CN 98810125A CN 98810125 A CN98810125 A CN 98810125A CN 1275915 A CN1275915 A CN 1275915A
- Authority
- CN
- China
- Prior art keywords
- dry
- fermentation
- fructus hordei
- hordei germinatus
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 39
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 title abstract description 5
- 238000000855 fermentation Methods 0.000 claims abstract description 50
- 230000004151 fermentation Effects 0.000 claims abstract description 50
- 239000007788 liquid Substances 0.000 claims abstract description 27
- 206010027476 Metastases Diseases 0.000 claims abstract description 21
- 230000009401 metastasis Effects 0.000 claims abstract description 21
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 28
- 230000005764 inhibitory process Effects 0.000 claims description 20
- 235000013311 vegetables Nutrition 0.000 claims description 19
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 18
- OLBNOBQOQZRLMP-UHFFFAOYSA-N SJ000286398 Natural products COC1=CC(=O)C=C(OC)C1=O OLBNOBQOQZRLMP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 11
- 229920002774 Maltodextrin Polymers 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 10
- 229940035034 maltodextrin Drugs 0.000 claims description 10
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000037213 diet Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 241000209140 Triticum Species 0.000 abstract 1
- 235000021307 Triticum Nutrition 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 48
- 230000000694 effects Effects 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 238000012545 processing Methods 0.000 description 12
- BCIBKWCJOCMBSI-UHFFFAOYSA-N 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione Chemical compound CCCCCCCCCCCCC1=CC(=O)C=C(OC)C1=O BCIBKWCJOCMBSI-UHFFFAOYSA-N 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000010911 splenectomy Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- 150000004059 quinone derivatives Chemical class 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- -1 methoxyl group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009533 lab test Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000004451 qualitative analysis Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000019362 perlite Nutrition 0.000 description 2
- 239000010451 perlite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- FKUYMLZIRPABFK-UHFFFAOYSA-N Plastoquinone 9 Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- FKUYMLZIRPABFK-IQSNHBBHSA-N plastoquinone-9 Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-IQSNHBBHSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/20—Malt products
- A23L7/25—Fermentation of cereal malt or of cereal by malting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Grain Derivatives (AREA)
- Steroid Compounds (AREA)
Abstract
Description
日期 | 2,6-DMBQ含量(mg/50g样品) | (σ%) | ||
04.27 | 3.45 | 3.54 | 3.66 | 0.08-2 |
04.28 | 3.27 | 3.68 | 3.31 | 0.18-5 |
05.10 | 1.56 | 1.49 | 1.48 | 0.03-1.9 |
05.10 | 3.65 | 3.42 | 0.12-3 | |
06.08 | 3.00 | 2.98 | 2.86 | 0.06-2 |
06.09 | 2.92 | 3.06 | 2.87 | 0.08-2.3 |
06.10 | 3.34 | 3.23 | 3.36 | 0.05-1.5 |
标准 | tR | k’ |
2,6-DMBQ | 13.4 | 5.0 |
2,6-DMBQ | 5.1 | 1.2 |
2,-MBQ | 8.5 | 2.7 |
处理 | 注射的细胞数 | 肝脏转移数 |
对照 | 3×104 | 104.0±28.2 |
冻干物 | 3×104 | 19.8±16.4* |
治疗 | 生长肿瘤的脾脏重量(g) | 肝脏转移数 |
对照,未进行脾脏切除 | 1.02±0.59 | 42.0±25.8 |
冻干物,未进行脾脏切除 | 0.62±0.47 | 19.5±19.0 |
对照,进行脾脏切除 | 0.10±0.02 | 19.1±13.5 |
*冻干物,进行脾脏切除 | 0.08±0.02 | 10.6±11.6 |
治疗 | 生长肿瘤的肢体的重量(平均) | 肺转移数(平均) |
对照 | 7.6±0.43 | 42.4±10.2 |
冻干物 | 7.2±0.38 | 6.2±3.7* |
处理 | 1μg/ml Con A | |
平均(cpm) | SEM | |
对照 | 3760.6 | 583.3 |
冻干物 | 8041.8 | 957.1 |
处理 | 排斥时间 | |||
雄性 | 雌性 | |||
平均(时间) | SEM | 平均(时间) | SEM | |
对照(未切除胸腺) | 21.0 | 3.1 | 28.7 | 4.5 |
对照(胸腺切除) | 52.4 | 5.0 | 41.6 | 5.5 |
冻干物(30mg/kg) | 28.8* | 8.6 | 32.6** | 4.5 |
Claims (12)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP9701392 | 1997-08-13 | ||
HU9701392A HUP9701392D0 (en) | 1997-08-13 | 1997-08-13 | Immunostimulating and methastasis-inhibiting plant extract, pharmaceutical compositions containing thereof, process for production of plant extract and use for production of immunostimulating and metastasis-inhibiting pharmaceutical composition thereof |
HUP9801797 | 1998-08-05 | ||
HU9801797A HU223344B1 (hu) | 1997-08-13 | 1998-08-05 | Immunstimuláns és metasztázist gátló fermentált, szárított anyag, ezt tartalmazó gyógyszerkészítmények, eljárás az előállítására és alkalmazásai |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1275915A true CN1275915A (zh) | 2000-12-06 |
CN1192099C CN1192099C (zh) | 2005-03-09 |
Family
ID=90014226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988101254A Expired - Fee Related CN1192099C (zh) | 1997-08-13 | 1998-08-11 | 植物性发酵物质及其制备方法及其应用以及含该物质的药用组合物和饮食添加剂 |
Country Status (31)
Country | Link |
---|---|
US (1) | US6355474B1 (zh) |
EP (1) | EP1003536B1 (zh) |
JP (3) | JP4387586B2 (zh) |
KR (2) | KR100544377B1 (zh) |
CN (1) | CN1192099C (zh) |
AT (1) | ATE227580T1 (zh) |
AU (1) | AU754815B2 (zh) |
BG (1) | BG64038B1 (zh) |
BR (1) | BR9811936B1 (zh) |
CA (1) | CA2300208C (zh) |
CZ (1) | CZ298654B6 (zh) |
DE (1) | DE69809434T2 (zh) |
DK (1) | DK1003536T3 (zh) |
EA (1) | EA003090B1 (zh) |
EE (1) | EE04222B1 (zh) |
ES (1) | ES2186208T3 (zh) |
GE (1) | GEP20032988B (zh) |
HK (1) | HK1033097A1 (zh) |
HU (1) | HU223344B1 (zh) |
ID (1) | ID25515A (zh) |
IL (1) | IL134493A (zh) |
ME (1) | ME00638B (zh) |
NO (1) | NO323562B1 (zh) |
PL (1) | PL191414B1 (zh) |
PT (1) | PT1003536E (zh) |
RS (1) | RS49692B (zh) |
SK (2) | SK1822000A3 (zh) |
TR (1) | TR200000404T2 (zh) |
UA (1) | UA67747C2 (zh) |
WO (1) | WO1999008694A1 (zh) |
YU (1) | YU7200A (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100718488B1 (ko) | 1998-04-24 | 2007-05-16 | 제네럴 일렉트릭 컴퍼니 | 실란 또는 실란 처리된 충전제를 이용하는 분말 피복제또는 접착제 |
FR2815822B1 (fr) * | 2000-10-30 | 2004-08-27 | Roquette Freres | Additif carbone pour fermentations alimentaires et compositions alimentaires le contenant |
FR2834718B1 (fr) * | 2002-01-15 | 2004-12-24 | Cognis France Sa | Substances actives cosmetiques et/ou pharmaceutiques |
ATE537836T1 (de) * | 2002-05-02 | 2012-01-15 | E L Management Corp | Verfahren zur verbesserung der biologischen aktivität von pflanzenextrakten |
HUP0202638A3 (en) * | 2002-08-09 | 2007-08-28 | Hidvegi Mate Dr | Use of fermented wheat-germ extract for preparation of antiphlogistic compositions |
MXPA05001725A (es) * | 2002-08-13 | 2005-05-27 | Mate Hidvegi | El uso de germen de trigo fermentado en la alimentacion y practica veterinaria. |
EA009170B1 (ru) * | 2002-08-13 | 2007-10-26 | Мате Хидвеги | Применение ферментированных зародышей пшеницы в ветеринарной практике |
EP2031975A1 (en) | 2006-05-24 | 2009-03-11 | Vitality Concepts Corporation | Method for embedding and targeted release of micronutrients in activated dietary fibers |
US7365102B1 (en) | 2007-02-26 | 2008-04-29 | Delphi Technologies, Inc. | Process for pre-reforming hydrocarbon fuels |
HUP0900614A2 (en) * | 2009-09-29 | 2011-05-30 | Mate Dr Hidvegi | Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production |
WO2010100515A2 (en) * | 2009-03-06 | 2010-09-10 | Hidvegi Mate | Fractions of wheat germ ferment |
JPWO2011083768A1 (ja) * | 2010-01-08 | 2013-05-13 | 住友ベークライト株式会社 | 細胞凝集塊形成用培養容器 |
US20120164132A1 (en) * | 2010-08-02 | 2012-06-28 | Mate Hidvegi | Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses |
GB201108560D0 (en) | 2011-05-20 | 2011-07-06 | 3 Ch Ltd | Use of fermented wheat germ in the treatment of inflammatory bowel disease |
GB201110746D0 (en) | 2011-06-23 | 2011-08-10 | Biropharma Uk Ltd | Wheat germ derived material |
US11129389B2 (en) | 2013-04-22 | 2021-09-28 | David Wales | Gluten-free grain-concentrate substitute for fermented wheat germ food product and method of preparation |
US11090353B2 (en) | 2013-04-22 | 2021-08-17 | David Wales | Gluten-free grain-concentrate substitute for fermented wheat germ drug product and method preparation |
JP2017033691A (ja) * | 2015-07-30 | 2017-02-09 | 三菱自動車工業株式会社 | 車載電池パック、リチウムイオン補充装置、及びリチウムイオン補充方法 |
CN107455551A (zh) * | 2016-06-06 | 2017-12-12 | 铜陵安尔生物科技有限公司 | 麦胚发酵黄酮提取物及其制备方法与在动物饲养中的应用 |
JP6739774B2 (ja) * | 2018-06-25 | 2020-08-12 | 学校法人立命館 | がんの治療、予防、改善、抑制又は転移抑制用組成物 |
EP3659444B1 (en) | 2018-11-27 | 2023-12-06 | Gyula Bencze | Gluten-free grain-concentrate substitute for fermented wheat germ food product and method of preparation |
WO2022091075A1 (en) * | 2020-11-01 | 2022-05-05 | Aili Life Sciences Ltd. | Combination compositions of probiotics with fermented wheat germ extract and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63230774A (ja) * | 1987-03-19 | 1988-09-27 | Seinosuke Ueda | 紫青系色素の製法 |
JP2618286B2 (ja) * | 1990-10-25 | 1997-06-11 | 免疫代謝薬製造株式会社 | 降圧酵母製剤及びその製造法 |
KR940001544B1 (ko) * | 1990-11-21 | 1994-02-24 | 강권중 | 은행잎을 위시한 천연약재로부터 미생물의 공서배양에 의한 건강식품의 제조방법 |
JP3296433B2 (ja) * | 1990-11-30 | 2002-07-02 | 日本食品化工株式会社 | 酒類の製造法 |
US5231017A (en) | 1991-05-17 | 1993-07-27 | Solvay Enzymes, Inc. | Process for producing ethanol |
EP0625187B1 (en) * | 1992-02-06 | 1997-04-23 | Bio-Technical Resources, Inc. | Concentrated beer flavor product |
SK283124B6 (sk) * | 1993-08-09 | 2003-02-04 | Edward Baral | Použitie trifenyletylénovej triedy antiestrogénov a kombinovaný prípravok na senzitivizáciu rakovinových buniek na lýzu zabíjačskými bunkami |
JPH07155136A (ja) * | 1993-12-03 | 1995-06-20 | Nippon Mektron Ltd | 植物発酵エキス粉末の製造方法 |
ATE202674T1 (de) * | 1993-12-24 | 2001-07-15 | Dsm Nv | Trockenhefe zusammensetzungen |
DE69428213T2 (de) * | 1994-01-06 | 2002-06-13 | Hyd Kutato-Fejleszto Ktf, Budapest | Nahrungsmittel zur verhinderung der entwicklung von erkrankungen und verfahren zur herstellung dieser nahrungsmittel |
JP3471879B2 (ja) * | 1994-01-20 | 2003-12-02 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | セリンキナーゼ活性の抑制方法、pi3−キナーゼのサブユニット間の結合活性の調整方法、pi3−キナーゼのサブユニット結合抗体、この抗体を生成するハイブリドーマ細胞系、核酸分子、プラスミド、アゴニスト、アンタゴニスト、pi3−キナーゼ活性を抑制するサブユニット結合分子、サブユニットの存在検出方法、pi3−キナーゼ活性の抑制剤製造方法、およびpi3−キナーゼ活性の抑制剤 |
JP2875739B2 (ja) * | 1994-04-27 | 1999-03-31 | エーザイ株式会社 | NFκB活性阻害剤 |
ES2142921T5 (es) * | 1994-05-27 | 2004-09-16 | Agrano Ag | Procedimiento de obtencion de una biomasa en un medio cerealista, utilizacion de los productos resultantes de este procedimiento y fermento de panificacion. |
JP4167733B2 (ja) * | 1996-12-16 | 2008-10-22 | 花王株式会社 | NF−κB活性化抑制剤 |
-
1998
- 1998-08-05 HU HU9801797A patent/HU223344B1/hu active IP Right Grant
- 1998-08-11 ID IDW20000424A patent/ID25515A/id unknown
- 1998-08-11 WO PCT/HU1998/000077 patent/WO1999008694A1/en active IP Right Grant
- 1998-08-11 JP JP2000509431A patent/JP4387586B2/ja not_active Expired - Lifetime
- 1998-08-11 ES ES98940483T patent/ES2186208T3/es not_active Expired - Lifetime
- 1998-08-11 PT PT98940483T patent/PT1003536E/pt unknown
- 1998-08-11 KR KR1020057013782A patent/KR100544377B1/ko not_active IP Right Cessation
- 1998-08-11 DE DE69809434T patent/DE69809434T2/de not_active Expired - Lifetime
- 1998-08-11 KR KR1020007001459A patent/KR100544376B1/ko not_active IP Right Cessation
- 1998-08-11 SK SK182-2000A patent/SK1822000A3/sk unknown
- 1998-08-11 YU YU7200A patent/YU7200A/sh unknown
- 1998-08-11 PL PL338891A patent/PL191414B1/pl unknown
- 1998-08-11 GE GEAP19985247A patent/GEP20032988B/en unknown
- 1998-08-11 CA CA002300208A patent/CA2300208C/en not_active Expired - Fee Related
- 1998-08-11 DK DK98940483T patent/DK1003536T3/da active
- 1998-08-11 AU AU88802/98A patent/AU754815B2/en not_active Ceased
- 1998-08-11 ME MEP-2000-72A patent/ME00638B/me unknown
- 1998-08-11 AT AT98940483T patent/ATE227580T1/de active
- 1998-08-11 CZ CZ20000418A patent/CZ298654B6/cs not_active IP Right Cessation
- 1998-08-11 TR TR2000/00404T patent/TR200000404T2/xx unknown
- 1998-08-11 BR BRPI9811936-2A patent/BR9811936B1/pt not_active IP Right Cessation
- 1998-08-11 RS YUP-72/00A patent/RS49692B/sr unknown
- 1998-08-11 IL IL13449398A patent/IL134493A/xx not_active IP Right Cessation
- 1998-08-11 EP EP98940483A patent/EP1003536B1/en not_active Expired - Lifetime
- 1998-08-11 EE EEP200000078A patent/EE04222B1/xx not_active IP Right Cessation
- 1998-08-11 SK SK186-2000A patent/SK282917B6/sk not_active IP Right Cessation
- 1998-08-11 CN CNB988101254A patent/CN1192099C/zh not_active Expired - Fee Related
- 1998-08-11 EA EA200000212A patent/EA003090B1/ru not_active IP Right Cessation
- 1998-08-13 US US09/485,221 patent/US6355474B1/en not_active Expired - Lifetime
- 1998-11-08 UA UA2000020979A patent/UA67747C2/uk unknown
-
2000
- 2000-02-10 NO NO20000675A patent/NO323562B1/no not_active IP Right Cessation
- 2000-03-06 BG BG104220A patent/BG64038B1/bg unknown
-
2001
- 2001-06-05 HK HK01103870A patent/HK1033097A1/xx unknown
-
2009
- 2009-07-21 JP JP2009170505A patent/JP4861458B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-01 JP JP2011168726A patent/JP4886087B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1192099C (zh) | 植物性发酵物质及其制备方法及其应用以及含该物质的药用组合物和饮食添加剂 | |
CN1240403C (zh) | 紫松果菊属组合物和制备方法 | |
TWI394566B (zh) | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds | |
CN1379082A (zh) | 樟芝的固体培养方法,所得固体培养物及其产品与用途 | |
CN1649610A (zh) | 一种用于加强温血动物的免疫、抗炎、抗肿瘤以及 d n a修复过程的植物水溶性提取物生物活性组分的分离纯化以及结构鉴定 | |
CN109929006B (zh) | 阿魏菇中麦角甾醇过氧化物的提取方法及应用 | |
Harada et al. | Effect of the medicinal mushroom, Grifola gargal (Agaricomycetes), on bone turnover markers and serum lipids in middle-aged and elderly Japanese women | |
US6616928B1 (en) | Active oxygen scavenger and cancer chemopreventer from Grifola | |
JP2004277414A (ja) | 食用キノコ由来のエストロゲン様活性物質 | |
CN1680290A (zh) | 姜酚肟及其合成与应用 | |
CN1171630C (zh) | 从香菇菌丝体的提取物来源的lak活性增强剂和含有此提取物的lak活性增强配方 | |
CN1245407C (zh) | 藤黄酸类化合物的复合物,其制备方法和以该复合物为活性成份的药物组合物 | |
CN1911258A (zh) | 桑寄生提取物及其制备方法和应用 | |
CN1323996C (zh) | 一个类木脂素及其制备方法和用途 | |
CN1580043A (zh) | 抗恶性肿瘤南柴胡萃取物的制备方法 | |
JPS61130235A (ja) | 感染症治療薬 | |
CN113786463A (zh) | 具有抑制肠道脂质吸收功能的小米全谷物黄酮的制备方法 | |
JPH07277971A (ja) | 抗腫瘍剤、ヒト腫瘍細胞に対する選択的細胞障害剤、ヘプテリジン酸クロロヒドリンの生産菌及びその製造方法 | |
MXPA00001557A (en) | Immunostimulatory and metastasis inhibiting fermented vegetal material | |
CN1114896A (zh) | 一种抗癌中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: FORMULA PATENT DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: TURMOSKURSINI FARKAS RITA LAPIS KAROLY ERZSEBET RASO BELA SZENDE Effective date: 20131127 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Budapest Patentee after: Marte Hidviji Patentee after: Formula food manufacturing & Trading Co.,Ltd. Address before: Budapest Patentee before: Marte Hidviji Patentee before: Formula Patent Development Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131127 Address after: Budapest Patentee after: Marte Hidviji Patentee after: Formula Patent Development Co.,Ltd. Address before: Budapest Patentee before: Marte Hidviji Patentee before: Farkas Rita Tomoskosini Patentee before: Caroli Rapis Patentee before: Bate Russo eucher Patentee before: Bela Shende |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050309 Termination date: 20160811 |
|
CF01 | Termination of patent right due to non-payment of annual fee |